Prophylaxis and treatment of cytomegalovirus infection after solid organ transplantation

Clinical Immunotherapeutics

Volumn 5, Issue 1, 1996, Pages 13-29

  Patel, Robin ^a   Wiesner, Russell H ^a   Paya, Carlos V ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; FAMCICLOVIR; FOSCARNET; GANCICLOVIR; IMMUNOGLOBULIN; INTERFERON; MONOCLONAL ANTIBODY; VALACICLOVIR; VIRUS VACCINE;

CYTOMEGALOVIRUS; HUMAN; IMMUNIZATION; INTRAVENOUS DRUG ADMINISTRATION; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; VIRUS INFECTION;

EID: 0030032190     PISSN: 11727039     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03259312     Document Type: Review

References (194)

1. Dummer JS, Hardy A, Poorsattar A, et al. Early infections in kidney, heart, and liver transplant recipients on cyclosporin. Transplantation 1983; 36: 259-67
2. Ho M. Advances in understanding cytomegalovirus infection after transplantation. Transplant Proc 1994; 26: 7-11
3. Stratta RJ. Clinical patterns and treatment of cytomegalovirus infection after solid-organ transplantation. Transplant Proc 1993; 25Suppl. 4: 15-21
4. Rook AH. Interactions of cytomegalovirus with the human immune system. Rev Infect Dis 1988; 10 Suppl. 3: S460-7
5. Fox AS, Tolpin MD, Baker AL, et al. Seropositivity in liver transplantation recipients as a predictor of cytomegalovirus disease. J Infect Dis 1988; 157: 383-4
6. Rubin RH. The indirect effects of cytomegalovirus infection on the outcome of organ transplantation. JAMA 1989; 261: 3607-9
7. van Son WJ, van der Berg AP, The TH, et al. Preemptive therapy with ganciclovir for early high-risk CMV infection allows effective treatment with antithymocyte globulin of steroidresistant rejection after renal transplantation. Transplant Proc 1993; 25: 1436-8
8. Boudreaux JP, Hayes DH, Mizrahi S, et al. Decreasing incidence of serious cytomegalovirus infection using ganciclovir prophylaxis in pédiatrie liver transplant patients. Transplant Proc 1993; 25: 1872
9. McCaughan GW, McDonald JA, Davies S, et al. Clinicopathological approach to human liver allograft dysfunction. J Gastroenterol Hepatol 1989; 4: 467-77
10. Shuster EA, Beneke JS, Tegmeier GE, et al. Monoclonal antibody for rapid laboratory detection of cytomegalovirus infections: characterization and diagnostic application. Mayo Clin Proc 1985; 60: 577-85
11. Van den Berg AP, Klimpmaker IJ, Haagsma EB, et al. Antigenemia in the diagnosis and monitoring of active cytomegalovirus infection after liver transplantation. J Infect Dis 1991 ; 164: 265-70
12. Van der Bij W, Schirm J, Torensma R, et al. Comparison between viremia and antigenemia for detection of cytomegalovirus in blood. J Clin Microbiol 1988; 26: 2531-5
13. Erice A, Holm MA, Gill PC, et al. Cytomegalovirus (CMV) antigenemia assay is more sensitive than shell vial cultures for rapid detection of CMV in polymorphonuclear blood leukocytes. J Clin Microbiol 1992; 30: 2822-5
14. Delgado R, Lumbreras C, Alba C, et al. Low predictive value of polymerase chain reaction for diagnosis of CMV disease in liver transplant recipients. J Clin Microbiol 1992; 30: 1876-8
15. Patel R, Smith TF, Espy M, et al. Detection of cytomegalovirus DNA in sera of liver transplant recipients. J Clin Microbiol 1994; 32: 1431-4
16. Spector SA, Merrill R, Wolf D, et al. Detection of human cytomegalovirus in plasma of AIDS patients during acute visceral disease by DNA amplification. J Clin Microbiol 1992; 30: 2359-65
17. Bitsch A, Kirchner H, Dupke R, et al. Cytomegalovirus transcripts in peripheral blood leukocytes of actively infected transplant patients detected by reverse transcription-polymerase chain reaction. J Infect Dis 1993; 167: 740-3
18. Paya CV, Smith TF, Ludwig J, et al. Rapid shell vial culture and tissue histology compared with serology for the rapid diagnosis of cytomegalovirus infection in liver transplantation. Mayo Clin Proc 1989:64:670-5
19. Smith TF, Shelley CD. Detection of IgM antibody to cytomegalovirus and rapid detection of this virus infection by the shell vial assay. J Virol Methods 1988; 21: 87-96
20. Marsano L, Perillo RP, Flye MW, et al. Comparison of culture and serology for the diagnosis of cytomegalovirus infection in kidney and liver transplant recipients. J Infect Dis 1990; 161:454-61
21. Littler E, Stuart AD, Crée MS. Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral analogue ganciclovir. Nature 1992; 358: 160-2
22. Sullivan V, Talarico CL, Stanat SC, et al. A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. Nature 1992; 358: 162-4
23. Keating MR. Antiviral agents. Mayo Clin Proc 1992; 67:160-78
24. Stratta RJ, Shaefer MS, Markin RS, et al. Clinical patterns of cytomegalovirus disease after liver transplantation. Arch Surg 1989; 142: 1433-50
25. Gudnason T, Belani KK, Balfour HH. Ganciclovir treatment of cytomegalovirus disease in immunocompromised children. Pediatr Infect Dis 1989; 8: 436-40
26. Mai M, Nery J, Sutker W, et al. DHPG (ganciclovir) improves survival in CMV pneumonia. Transplant Proc 1989; 21: 2263-5
27. D'Allesandro AM, Pirsch JD, Stratta RJ, et al. Successful treatment of severe cytomegalovirus infections with ganciclovir and CMV hyperimmune globulin in liver transplant recipients. Transplant Proc 1989; 21: 3560-1
28. Salmela K, Hocherstedt K, Lautenschlager I, et al. Ganciclovir in the treatment of severe cytomegalovirus disease in liver transplant patients. Transplant Proc 1990; 22: 238-40
29. de Hemptinne B, Lamy ME, Salizzoni M, et al. Successful treatment of cytomegalovirus disease with 9-(l,3-dihydroxy-2propoxymethyl guanine). Transplant Proc 1988; 20: 652-5
30. Buhles WC, Mastre BJ, Tinker AJ, et al. Ganciclovir treatment of life- or sight-threatening cytomegalovirus infection: experience in 314 immunocompromised patients. Rev Infect Dis 1988; 106: S495-506
31. de Koning J, van Dorp WT, van Es LA, et al. Ganciclovir effectively treats cytomegalovirus disease after solid-organ transplantation, even during rejection treatment. Nephrol Dial Transplant 1992; 7: 350-6
32. Lang P, Buisson C, Rostoker G, et al. DHPG treatment of kidney transplant recipients with severe CMV infection. Transplant Proc 1989; 21: 2084-6
33. Guerin C, Pozzetto B, Broyet C, et al. Ganciclovir therapy of symptomatic cytomegalovirus infection in renal transplant recipients. Nephrol Dial Transplant 1989; 4: 906-10
34. Jordan ML, Hrebinko Jr.RL, Dummer JS, et al. Therapeutic use of ganciclovir for invasive cytomegalovirus infection in cadaveric renal allograft recipients. J Urol 1992; 148: 1388-92
35. Nicholson ML, Veitch PS, Donnelly PK, et al. Treatment of renal transplant-associated cytomegalovirus infection with ganciclovir. Transplant Proc 1990; 22: 1811-2
36. Cerrina J, Bavoux E, Ladurie FL, et al. Ganciclovir treatment of cytomegalovirus infection in heart-lung and double-lung transplant recipients. Transplant Proc 1991; 23: 1174-5
37. Cooper DKC, Novitzky D, Schlegel V, et al. Successful management of symptomatic cytomegalovirus disease with ganciclovir after heart transplantation. J Heart Lung Transplant 1991; 10:656-63
38. Icenogle TB, Peterson E, Ray G, et al. DHPG effectively treats CMV infection in heart and heart-lung transplant patients: a preliminary report. J Heart Transplant 1987; 6: 199-203
39. Keay S, Petersen E, Icenogle T, et al. Ganciclovir treatment of serious cytomegalovirus infection in heart and heart-lung transplant recipients. Rev Infect Dis 1988; lOSuppl. 3: S563-72
40. Snydman DR. Ganciclovir Iherapy for cytomegalovirus disease associated with renal transplants. Rev Infect Dis 1988: 10 Suppl. 3: S554-62
41. Rondeau E. Parquet C, Ruedin P, et al. Efficacy of early treatment of cytomegalovirus infection by ganciclovir in renal transplant recipients. Transplant Proc 1990; 22: 1813-4
42. Hrebinko R, Jordan ML, Dummer JS, et al. Ganciclovir for invasive cytomegalovirus infection in renal allograft recipients. Transplant Proc 1991:23: 1346-7
43. Watson FS, O'Connell JB, Amber IJ, et al. Treatment of cytomegalovirus pneumonia in heart transplant recipients with 9-( 1,3-dihydroxy-2-proproxymethyl)-guanine (DHPG). J Heart Transplant 1988; 7: 102-5
44. Steinhoff G, Behrend M. Wagner TOP, et al. Early diagnosis and effective treatment of pulmonary CMV infection after lung transplantation. J Heart Lung Transplant 1991 ; 10:9-14
45. Smyth RL, Scott JP, Borysiewicz LK, et al. Cytomegalovirus infection in heart-lung transplant recipients: risk factors, clinical associations, and response to treatment. J Infect Dis 1991: 164: 1045-50
46. Dünn DL, Mayoral JL, Gillingham KJ, et al. Treatment of invasive cytomegalovirus disease in solid organ transplant patients with ganciclovir. Transplantation 1991 ; 51: 98-106
47. Megison SM, Andrews WS. Combination therapy with ganciclovir and intravenous IgG for cytomegalovirus infections in pédiatrie liver transplant recipients. Transplantation 1991 ; 52: 151-4
48. Stein DS, Verano AS, Levandowski RA. Successful treatment with ganciclovir of disseminated cytomegaiovirus infection after liver transplantation. Am J Gastroenterol 1988; 83: 684-6
49. Paya CV, Hermans PE, Smith TF, et al. Efficacy of ganciclovir in liver and kidney transplant recipients with severe cytomegalovirus infection. Transplantation 1988; 46: 229-34
50. Markin RS, Langnas AN, Donovan JP, et al. Opportunistic viral hepatitis in liver transplant recipients. Transplant Proc 1991 ; 23: 1520-1
51. Winston DJ, Ho WG, Bartomi K, et al. Ganciclovir therapy for cytomegalovirus infections in recipients of bone marrow transplants and other immunosuppressed patients. Rev Infect Dis 1988; 10: S547-53
52. Erice A, Jordan MC, Chace BA, et al. Ganciclovir treatment of cytomegalovirus disease in transplant recipients and other immunocompromised hosts. JAMA 1987; 257: 3082-7
53. Harbison MA, De-Girolami PC, Jenkins RL, et al. Ganciclovir therapy of severe cytomegalovirus infections in solid-organ transplant recipients. Transplantation 1988; 46: 82-8
54. O' Hair DP, Johnson CP, Roza AM, et al. Treatment of transplant rejection in the presence of cytomegalovirus viremia. Transplant Proc 1990; 22: 1815-7
55. Ross CN, Reynon HLC, Savill JS, et al. Ganciclovir treatment for cytomegalovirus infection in immunocompromised patients with renal disease. Q J Med 1991 ; 81: 929-36
56. Stratta R, Shaefer M, Markin R, et al. Ganciclovir therapy for viral disease in liver transplant recipients. Transplant Proc 1991; 23: 1968
57. Reed EC, Wolford JL, Kopecky KJ, et al. Ganciclovir for the treatment of cytomegalovirus gastroenteritis in bone marrow transplant patients. Ann Intern Med 1990; 112: 505-10
58. Swan SK, Munar MY, Wigger MA, et al. Pharmacokinetics of ganciclovir in a patient undergoing hemodialysis. Am J Kidney Dis 1991: 17:69-72
59. Sayage LH, Gonwa TA, Goldstein RM, et al. Cytomegalovirus infection in orthotopic liver transplantation. Transplant Int 1989; 2: 96-101
60. Davis CL, Springmeyer S, Gmerek BJ. Central nervous system side effects of ganciclovir. N Engl J Med 1990; 322: 933-4
61. Shea BF, Huffman S. Sesin GP, et al. Ganciclovir hepatotoxicity. Pharmacotherapy 1987; 7: 223-6
62. Faulds D, Heel RC. Ganciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytornegalovirus infections. Drugs 1990; 39: 597-638
63. Buhles WC, Mastre BJ, Tinker AJ. Ganciclovir treatment of life- or sight-threatening Cytomegalovirus infection: experience in 314 immunocompromised patients. Rev Infect Dis 1988; 10: S495-506
64. Dünn DL, Mayoral JL, Gillingham KJ, et al. Treatment of invasive cytomegalovirus disease in solid organ transplant patients with ganciclovir. Transplantation 1991; 51: 98-106
65. De Armond B. Safety considerations in the use of ganciclovir in immunocompromised patients. Transplant Proc 1991; 23 Suppl. 1:26-9
66. Boivin G, Erice A, Crane DD, et al. Ganciclovir susceptibilities of cytomegalovirus (CMV) isolates from solid organ transplant recipients with CMV viremia after antiviral prophylaxis. J Infect Dis 1993; 168: 322-5
67. Einsele H, Ehninger G, Steidle M, et al. Polymerase chain reaction to evaluate antiviral therapy for cytomegalovirus disease. Lancet 1991; 338: 1170-2
68. van den Berg AP, van Son WJ, Haagsma EB, et al. Prediction of recurrent cytomegalovirus disease after treatment with ganciclovir in solid-organ transplant recipients. Transplantation 1993:55:847-51
69. Sawyer MD, Mayoral JL, Gillingham KJ, et al. Treatment of recurrent cytomegalovirus disease in patients receiving solid organ transplants. Arch Surg 1993; 128: 165-70
70. Klintmalm G, Lonnqvist B, Oberg B, et al. Intravenous foscarnet for the treatment of severe cytomegalovirus infection in allograft recipients. Scand J Infect Dis 1985; 17: 157-63
71. Barkholt LM, Ericzon BG, Ehrnst A, et al. Cytomegalovirus infections in liver transplant patients: incidence and outcome. Transplant Proc 1990; 22: 235-7
72. Ringdén O, Lonnqvist B, Paulin T, et al. Pharmacokinetics, safety and preliminary clinical experiences using foscarnet in the treatment of cytomegalovirus infections in bone marrow and renal transplant recipients. J Antimicrob Chemother 1986: 17: 373-87
73. Locke TJ, Odom NJ, Tapson JS, et al. Successful treatment with trisodium phosphonoformate for primary cytomegalovirus infection after heart transplantation. J Heart Transplant 1987: 6: 120-2
74. Manischewits JE, Guinnan GV, Lane HC, et al. Synergistic effect of ganciclovir and foscarnet on Cytomegalovirus replication in vitro. Antimicrob Agents Chemother 1990; 34: 373-5
75. Wade JC, Hintz M. McGuffm RW, et al. Treatment of cytomegalovirus pneumonia with high dose acyclovir. Am J Med 1982; 73: 249-56
76. Burdelski M, Schmidt K, Hoyer PF, et al. Liver transplantation in children: the Hanover experience. Transplant Proc 1987; 19:3277-81
77. Lautenschlager I, Ahonen J, Eklund B, et al. Hyperimmune globulin therapy of clinical CMV disease in renal allograft recipients. Transplant Proc 1989; 21: 2087-8
78. Rancewicz Z, Halama G. Smogorzewski M, et al. The usefulness of hyperimmune globulin for treatment of overt cyto-megalovirus infection in allograft recipients. Transplant Proc 1990; 22: 1818-9
79. Stratta RJ, Wood RP, Langnas RM, et al. Donor selection for orthotopic liver transplantation: lack of an effect of gender of cytomegalovirus (CMV) status. Transplant Proc 1990; 22: 410-3
80. Bowden RA, Sayers MH, Cays M, et al. The role of blood product filtration in the prevention of transfusion associated cytomegalovirus (CMV) infection after marrow transplant [abstract no. S205]. Transfusion 1989; 27: 575
81. Sayers MH, Andersen KC, Goodnough LT, et al. Reducing the risk for transfusion-transmitted cytomegalovirus infection. Ann Intern Med 1992; 116:55-62
82. Milbradt H, Flik J, Stangel W, et al. Bedeutung der Untersuchung auf Antikörper gegen Cycomegalievirus bei Organtransplantationen. Beitr Infusionsther 1990; 26: 33-6
83. Rakela J, Wiesner RH, Taswell HF, et al. Incidence of cytomegalovirus infection and its relationship to donor-recipient sérologie status in liver transplantation. Transplant Proc 1987;19: 2399-402
84. Marker SC, Simmons RL, Balfour Jr.HH. Cytomegalovirus vaccine in renal allograft recipients. Transplant Proc 1981; 13: 117-9
85. Balfour Jr.HH, Sachs GW, Welo P, et al. Cytomegalovirus vaccine in renal transplant candidates: progress report of a randomized, placebo-controlled, double-blind trial. Birth Defects 1984; 20: 289-304
86. Balfour Jr.HH, Welo PK, Sachs GW. Cytomegalovirus vaccine trial in 400 renal transplant candidates. Transplant Proc 1985; 17:81-3
87. Glazer JP, Friedman HM, Grossman RA, et al. Live cytomegalovirus vaccination of renal transplant candidates. A preliminary trial. Ann Intern Med 1979; 91: 676-83
88. Plotkin SA, Huang E-S. Cytomegalovirus vaccine virus (Towne strain) does not induce latency. J Infect Dis 1985; 152: 395-7
89. Brayman KL, Dafoe DC, Smythe WR, et al. Prophylaxis of serious cytomegalovirus infection in renal transplant candidates using live human cytomegalovirus vaccine. Arch Surg 1988; 123: 1502-8
90. Plotkin SA, Starr SE, Friedman HM, et al. Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant. Ann Intern Med 1991; 114: 525-31
91. Plotkin SA, Friedman HM, Fleisher GR, et al. Towne-vaccineinduced prevention of cytomegalovirus disease after renal transplants. Lancet 1984; i: 528-30
92. Plotkin SA, Gonczol E, Starr SE. Subunit vaccine against human cytomegalovirus (HCMV) [abstract no. 735[. Proceedings of Interscience Conference on Antimicrobial Agents and Chemotherapy, 1988
93. Adler SP. Development and clinical status of cytomegalovirus vaccines. Clin Immunother 1994; 2(1): 1-6
94. Britt W, Fay J, Seals J, et al. Formulation of an immunogenic human cytomegalovirus vaccine: responses in mice. J Infect Dis 1995; 171: 18-25
95. Bj0ro K. Fr01and SS. Yun Z, et al. Hepatitis C infection in patients with hypogammaglobulinemia after treatment with contaminated immune globulin. N Engl J Med 1994; 331: 1607-11
96. Gorensek MJ, Carey WD, Vogt D, et al. A multivariate analysis of risk factors for cytomegalovirus infection in liver transplant recipients. Gastroenterology 1987; 156: 273-9
97. Pan SH, Rosenthal P, Howard TK, et al. Evaluation of three cytomegalovirus infection prophylactic regimens in liver transplant recipients. Transplant Proc 1992; 24: 1466-7
98. Dussaix E, Wood C. Cytomegalovirus infection in pédiatrie liver recipients: a virologie survey and prophylaxis with CM V immunoglobulin and early DHPG treatment. Transplantation 1989; 48: 272-4
99. Cofer JB, Morris ÇA, Sutker WL, et al. A randomized doubleblind study of the effect of prophylactic immune globulin on the incidence and severity of CM V infection in the liver transplant recipient. Transplant Proc 1991; 23: 1525-7
100. Snydman DR, Werner BG, Dougherty NN, et al. for the Boston Center for Liver Transplantation CMVIG Study Group. Cytomegalovirus immune globulin prophylaxis in liver transplantation: a randomized, double blind, placebo-controlled trial. Ann Intern Med 1993; 10: 984-91
101. Bell R, Sheil AGR, McDonald JA, et al. The role of CMV immune prophylaxis in patients at risk of primary CMV infection following orthotopic liver transplantation. Transplant Proc 1989; 21:3781-2
102. Saliba F, Gugenheim J, Samuel D, et al. Incidence of cytomegalovirus infection and effects of Cytomegalovirus immune globulin prophylaxis after orthotopic liver transplantation. Transplant Proc 1987; 19: 4081-2
103. Saliba F, Arulnaden JL, Gugenheim J, et al. CMV hyperimmune globulin prophylaxis after liver transplantation: a prospective randomized controlled study. Transplant Proc 1989; 21: 2260-2
104. Stratta RJ, Shaeffer MS, Cushing KA, et al. Successful prophylaxis of Cytomegalovirus disease after primary CMV exposure in liver transplant recipients. Transplantation 1991 ; 51: 90-7
105. Stratta RJ, Shaeffer MS, Cushing KA, et al. A randomized prospective trial of acyclovir and immune globulin prophylaxis in liver transplant recipients receiving OKT3 therapy. Arch Surg 1992; 127: 55-64
106. Kaden J, Scholz D, Eichler C, et al. Frequency of infection with cytomegaloviruses (CMV) following kidney transplantation and initial experiences with CMV gamma globulin prevention. Immun Infekt 1985; 13: 290-5
107. Greger B, Vallbracht A, Kurth J, et al. The clinical value of CMV prophylaxis by CM V hyperimmune serum in the kidney transplant patient. Transplant Proc 1986; 18: 1387-9
108. Snydman DR, Werner BG, Heinze-Lacey B, et al. Use of cytomegalovirus immune globulin to prevent Cytomegalovirus disease in renal-transplant recipients. N Engl J Med 1987; 317: 1049-54
109. Grundmann R, Wienand P, Runde A, et al. Cytomegalovirus hyperimmunoglobulin prophylaxis following kidney transplantation. Results of a prospective randomized study. Dtsch Med Wochenschr 1987; 112: 827-31
110. Light JA, Khawand N, Brems W, et al. Does IVIG prevent primary CMV disease in kidney transplant recipients, [abstract]. American Academy of Transplant Physicians Annual Meeting, Chicago, 1988
111. Fehir KM, Decker WA, Samo T, et al. Immune globulin (Gammagard) prophylaxis of CMV infections in patients undergoing organ transplantation and allogenic bone marrow transplantation. Transplant Proc 1989; 21: 3107-9
112. Kasiske BL, Heim-Duthoy KL, Tortorice KL, et al. Polyvalent immune globulin and Cytomegalovirus infection after renal transplantation. Arch Intern Med 1989; 149: 2733-6
113. Metselaar HJ, Rothbarth PH, Brouwer RM, et al. Prevention of cytomegalovirus-related death by passive immunization. A double-blind placebo-controlled study in kidney transplant recipients treated by rejection. Transplantation 1989; 48: 264-6
114. Steinmuller DR, Novick AC, Streem SB, et al. Intravenous immunoglobulin infusions for the prophylaxis of secondary Cytomegalovirus infection. Transplantation 1990; 49: 68-70
115. Cofer JB. Morris CA. Sutker BS, et af. A randomized double-blind study of the effect of prophylactic immune globulin on the incidence and severity of CMV infection in the liver transplant recipient. Transplant Proc 1983; 15: 1405-11
116. Conti DJ, Freed BM, Gruber SA. et al. Prophylaxis of primary cytomegalovirus disease in renal transplant patients. Arch Surg 1994; 129: 443-7
117. Finn WF. CMV-enriched immune globulin produces consistent reliable results in renal transplant patients. Transplantation 1993:56:491-3
118. Werner BG, Snydman DR, Freeman R, et al. Cytomegalovirus immune globulin for the prevention of primary CMV disease in renal transplant patients. Analysis of usage under treatment IND status. Transplant Proc 1993; 25: 1441-3
119. Balk AHMM, Weiman W. Rothbarth PH, et al. Passive immunization against cytomegalovirus in allograft recipients. The Rotterdam heart transplant experience. Infection 1993: 21: 195-200
120. Tenschert W, Gonnermann D, Meyer-Moldenhauer WH, et al. Management of cytomegalovirus infection in high-risk recipients after renal transplantation: prophylaxis by hyperimmune globulins or DHPG treatment? Transplant Proc 1993; 25: 3256-8
121. Bailey TC, Ettinger NA, Storch GA, et al. Failure of high-dose oral acyclovir with or without globulin to prevent primary cytomegalovirus disease in recipients of solid organ transplants. Am J Med 1993: 95: 273-8
122. Snydman DR. Werner BG, Dougherty NN, et al. A further analysis of the use of cytomegalovirus immune globulin in orthotopic liver transplant recipients at risk for primary infection. Transplant Proc 1994; 26: 23-7
123. Conti DJ, Freed BM, Gruber SA, et al. Prophylaxis of primary cytomegalovirus disease in renal transplant patients. Arch Surg 1994; 129:443-7
124. Zamora MR, Fullerton DN, Campbell et al. Use of cytomegalovirus (CMV) hyperimmune globulin for prevention of CMV disease in CMV-seropositive lung transplant recipients. Transplant Proc 1994:26:49-51
125. BasadonnaG, Feria A, PerezR. et al. Incidence of infection and acute rejection after cytomegalovirus immune globulin prophylaxis in renal transplantation. Transplant Proc 1994; 26: 52 3
126. Prian GW. Koep LJ. Elimination ofcytomegalovirusdisea.se in liver transplant patients treated prophylactically with combination cytomegalovirus hyperimmune globulin and ganciclovir. Transplant Proc 1994; 26: 54-5
127. Nichol DL, MacDonald AS, Belitsky P. et al. Reduction by combination prophylactic therapy with CMV hyperimmune globulin and acyclovir of the risk of primary CMV disease in renal transplant recipients. Transplantation 1993; 55: 841-6
128. Khawand N, Light JA. Brems W, et al. Does intravenous immunoglobulin prevent primary cytomegalovirus disease in kidney transplant recipients? Transplant Proc 1989; 21: 2072-4
129. Weimar W. Metselaar HJ, Balk AHMM, et al. Passive immunization to prevent cytomegalovirus disease after kidney and heart transplantation. Transplant Proc 1990: 22: 229-32
130. Gould FK. Freeman R, Taylor CE, et al. Prophylaxis and management of cytomegalovirus pneumonitis after lung transplantation: a review of experience in one center. J Heart Lung Transplant 1993; 12:695-9
131. Dreikorn K, Doerr H-W, Guersen RG. Cytomegalovirus (CMV) infections in renal transplant recipients. Preliminary results of prophylaxis by an intramuscular hyperimmune CMV IgG. Scand J Urol Nephrol Suppl 1985: 92: 15-21
132. Havel MR Laczkovics AM, Wolner E. et al. Prophylactic use of hyperimmunoglobulin for cytomegalovirus infection in heart transplantation. Clin Ther 1989; 11: 472-8
133. Steinmuller DR. Graneto D, Swift C, et al. Use of intravenous immunoglobulin prophylaxis for primary cytomegalovirus infection post living-related-donor renal transplantation. Transplant Proc 1989:21:2069-71
134. Tenschert W, Gonnermann D, Meyer-Moldenhauer W-H. et al. Management of cytomegalovirus infection in high-risk recipients after renal transplantation: prophylaxis by hyperimmunoglobulins or DHPG treatment? Transplant Proc 1993: 25: 3256-8
135. Metselaar HJ, Balk AHMM, Mochtar B. et al. Cytomegalovirus seronegative heart transplant recipients. Prophylactic use of anti-CMV immunoglobulin. Chest 1990; 97: 396-9
136. Gorensek M, Carey WD, Vogt D, et al. A multivariate analysis of risk factors for cytomegalovirus infection in liver transplant recipients. Gastroenterology 1990; 98: 1326-32
137. Fassbinder W. Ernst W. Hanke P. et al. Cytomegalovirus infections after renal transplantation: effect of prophylactic hyperimmunoglobulin. Transplant Proc 1986; 18: 1393-6
138. Glowacki LS, Smaill FM. Use of immune globulin to prevent symptomatic cytomegalovirus disease in transplant recipients - a meta-analysis. Clin Transplant 1994; 8: 10-8
139. Cheeseman SH, Rubin RH, Stewart JA. et al. Controlled clinical trial of prophylactic human-leukocyte Interferon in renal transplantation. N Engl J Med 1979; 300: 1345-9
140. Hirsch MS. Schooley RT, Cosimii AB. et al. Effect of interferon-alpha on cytomegalovirus reactivation syndromes in renal transplant recipients. N Engl J Med 1983; 308: 1489-93
141. Weimer W, Lameijer DF. Edy VG. et al. Prophylactic use of interferon in renal allograft recipients. Transplant Proc 1979; 11:69-70
142. Kovariak J. Mayer G, Pohanka E, et al. Adverse effect of lowdose prophylactic human recombinant leukocyte interferonalpha treatment in renal transplant recipients. Transplantation 1988:45:402-5
143. Weimar W, Kramer P, Bijnen AB, et al. The incidence of cytomegalo- and herpes simplex virus infections in renal allograft recipients treated with high dose recombinant leukocyte interferon: a controlled trial. Scand J Urol Suppl 1985: 92: 37-9
144. Davis CL. The prevention of cytomegalovirus disease in renal transplantation. Am J Kidney Dis 1990; 16: 175-88
145. Lui SF, AH AA, Grundy JE, et al. Double-blind, placebocontrolled trial of human lymphoblastoid interferon prophylaxis of cytomegalovirus infection in renal transplant recipients. Nephrol Dial Transplant 1992; 7: 1230-7
146. MacDonald AS. Belitsky P, Cohen A. et al. Cytomegalovirus disease prophylaxis in seronegative recipients of kidneys from seropositive donors by combination of cytomegalovirushyperimmune globulin and low-dose acyclovir. Transplant Proc 1991; 23: 1355-6
147. Vasquez EM. Sanchez J. Pollak R. et al. High-dose oral acyclovir prophylaxis for primary cytomegalovirus infection in seronegative allograft recipients. Transplantation 1993:55: 448-50
148. LegendreC, Ducloux D. Ferroni A, et al. Acyclovir in preventing cytomegalovirus infection in kidney transplant recipients: a case-controlled study. Transplant Proc 1993; 25: 1431 -3
149. Wong T. Lavaud S, Toupance O, et al. Failure of acyclovir to prevent cytomegalovirus infection in renal allograft recipients. Transplant Proc 1993: 6: 285-9
150. Barton IK, Nicholson. Use of pooled immunoglobulin and acyclovir as prophylaxis against cytomegalovirus disease in recipients of renal allografts. Nephrol Dial Transplant 1991 ; 6: 524-6
151. Elkhammas EA, Henry ML, Tesi RJ, et al. Cytomegalovirus prevention in combined kidney-pancreas transplantation using acyclovir alone. Transplant Proc 1994; 26: 436
152. Eisenmann D, KnippH, Laube H, et al. Prevention of cytomegalovirus disease in heart transplant recipients by prophylaxis with cytomegalovirus hyperimmune globulin plus oral acyclovir. Transplant Proc 1990; 22: 2322-3
153. Mollison LC, Richards MJ, Johnson PDR, et al. High-dose oral acyclovir reduces the incidence of cytomegalovirus infection in liver transplant recipients. J Infect Dis 1993; 168: 721-4
154. Kizilisik TA, Preiksaitis JK, Kneteman NM. Cytomegalovirus disease in liver transplant recipients: impact of acyclovir prophylaxis. Transplant Proc 1993; 25: 2282-3
155. Saliba F, Eyraud D, Samuel D, et al. Randomized controlled trial of acyclovir for the prevention of cytomegalovirus infection and disease in liver transplant recipients. Transplant Proc 1993; 25: 1444-5
156. Green M, Reyes J, Nour B, et al. Randomized trial of ganciclovir followed by high dose oral acyclovir vs ganciclovir alone in the prevention of cytomegalovirus disease in pédiatrie liver transplant recipients: preliminary analysis. Transplant Proc 1994; 26: 173-4
157. Elkins CC, Frist WH, Dummer S, et al. Cytomegalovirus disease after heart transplantation. Is acyclovir indicated. Ann Thorac Surg 1993; 56: 1267-73
158. Balfour HH, Chace B A, Stapleton JT, et al. A randomized placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N Engl J Med 1989; 320: 1381-7
159. Martin FM, Manez R, Linden P, et al. A prospective randomized trial comparing sequential ganciclovir-high dose acyclovir to high dose acyclovir for prevention of cytomegalovirus disease in adult liver transplant recipients. Transplantation 1994; 58: 779-85
160. Balfour HH, Fletcher CV, Dünn D. Prevention of cytomegalovirus disease with oral acyclovir. Transplant Proc 1991; 23: 17-9
161. Frey DJ, Matas AJ, Gillingham KJ, et al. Sequential therapy a prospective randomized trial of MALG versus OKT3 for prophylactic immunosuppression in cadaver renal allograft recipients. Transplantation 1992; 54: 50-6
162. Boivin G, Erice A, Crane DD, et al. Acyclovir susceptibilities of herpes simplex virus strains isolated from solid organ transplant recipients after acyclovir or ganciclovir prophylaxis. Antimicrob Agents Chemother 1993; 37: 357-9
163. Rondeau E, Bourgeon B, Peraldi MN, et al. Effect of prophylactic ganciclovir on cytomegalovirus infection in renal transplant recipients. Nephrol Dial Transplant 1993; 8: 858-62
164. Dunn DL, Gillingham KJ, Kramer MA, et al. A prospective randomized study of acyclovir versus ganciclovir plus human immune globulin prophylaxis of cytomegalovirus infection after solid organ transplantation. Transplantation 1994; 57: 876-84
165. Duncan SR, Grgurich WF, laceno AT, et al. A comparison of ganciclovir and acyclovir to prevent cytomegalovirus after lung transplantation. Am J Respir Crit Care Med 1994; 150: 146-52
166. Nakazato PZ, Burns W, Moore P, et al. Viral prophylaxis in hepatic transplantation: preliminary report of a randomized trial of acyclovir and ganciclovir. Transplant Proc 1993; 25: 1935-7
167. Bailey TC, Trulock EP, Ettinger NA, et al. Failure of prophylactic ganciclovir to prevent cytomegalovirus disease in recipients of lung transplants. J Infect Dis 1992; 165: 48-52
168. Portela D, Patel R, Keating MR, et al. A randomized controlled trial evaluating ganciclovir followed by high dose acyclovir versus acyclovir in the prophylaxis of cytomegalovirus infection in liver transplantation [abstract]. Second Congress of the International Liver Transplantation Society, Toronto, Canada, 1993
169. Cohen AT, O'Grady JG, Sutherland S, et al. Controlled trial of prophylactic versus therapeutic use of ganciclovir in liver transplantation in adults. J Med Virol 1993; 40: 5-9
170. Merigan TC, Renlund DG, Keay S, et al. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. N Engl J Med 1992; 326: 1182-6
171. Laske A, Gallino A, Mohacsi P, et al. Prophylactic treatment with ganciclovir for cytomegalovirus infection in heart transplantation. Transplant Proc 1991;23: 1170-3
172. Duncan SR, Paradis IL, Dauber JH, et al. Ganciclovir prophylaxis for cytomegalovirus infections in pulmonary allograft recipients. Rev Respir Dis 1992; 146: 1213-5
173. Preise CE, Pons V, Lake J, et al. Comparison of three regimens for cytomegalovirus prophylaxis in 147 liver transplant recipients. Transplant Proc 1991; 23: 1498-500
174. Winston DJ, Wirin D, Snaked A, et al. Randomised comparison of
175. Aguado JM, Gomez-Sanchez MA, Lumbreras C, et al. Prospective randomized trial of efficacy of ganciclovir versus that of anti-cytomegalovirus (CMV) immunoglobulin to prevent CMV disease in CMV-seropositive heart transplant recipients treated with OKT3. Antimicrob Agents Chemother 1995; 39: 1643-5
176. Maurer JR, Snell G, de Hoyos A, et al. Outcomes of lung transplantation using three different cytomegalovirus prophylactic regimens. Transplant Proc 1993; 25: 1434-5
177. Stratta RJ, Taylor RJ, Byron TJ. Viral prophylaxis in combined pancreas-kidney transplant patients. Transplantation 1994; 57: 506-12
178. Harland RC, Vernon WB, Bunzendahl H, et al. Ganciclovir/acyclovir prophylaxis reduces the incidence of cytomegalovirus infections in pancreas transplant recipients. Transplant Proc 1994; 26: 432-3
179. Spector SA, McKinley G, Drew WL, el al. A randomized, doubleblind study of the efficacy and safety of oral ganciclovir for the prevention of cytomegalovirus disease in HIV-infected persons [abstract]. Proc ICAAC 34th; Orlando FL; 1994
180. Bailey TC. Prevention of cytomegalovirus disease. Sem Respir Infect 1993; 8: 225-32
181. Rubin RH, Tolkoff-Rubin NE. Antimicrobial strategies in the care of organ transplant recipients. Antimicrob Agents Chemother 1993; 37: 619-24
182. Singh N, Yu VL, Mietes L, et al. High-dose acyclovir compared with short-course preemptive therapy to prevent cytomegalovirus disease in liver transplant recipients. A randomized trial. Ann Intern Med 1994; 120: 375-81
183. Cagle PT, Buttone G, Holland VA, et al. Semiquanlitative measurement of cytomegalovirus DNA in lung and heart-lung transplant patients by in vitro DNA amplification. Chest 1992; 101:93-6
184. Pate] R, Smith TF. Espy M, et al. Detection of cytomegalovirus DNA in sera of iiver transplant recipients. J Clin Microbiol 1994;32: 1431-4
185. IbererF, Halwachs-Baumann G, Rodi S, etal. Monitoring cytomegalovirus disease after heart transplantation. Persistence of anti-cytomegalovirus IgM antibodies. J Heart Lung Transplant 1994; 13:405-11
186. Portela D. Patel R, Larson-Keller JJ, et al. OKT3 treatment for allograft rejection is a risk factor for CMV disease in liver transplantation. J Infect Dis. In press
187. Hibberd PL, Tolkoff-Rubin NE, Cosimi AB, et al. Symptomatic cytomegalovirus disease in the cytomegalovirus antibody seropositive renal transplant recipient treated with OKT3. Transplantation 1992; 53: 68-72
188. Prokurats S, Drabik E, Genda R. et al. Ganciclovir in cytomegalovirus prophylaxis in high-risk pédiatrie renal transplant patients. Transplant Proc 1993; 25: 2577
189. So S, Mayo C. McCullough C, et al. Cytomegalovirus prophylaxis in pédiatrie renal transplant recipients. Transplant Proc 1993; 25: 1414-5
190. Lumbreras C, Otero JR, Herrero JA, et al. Ganciclovir prophylaxis decreases frequency and severity of cytomegalovirus disease in seropositive liver transplant recipients treated with OKT3 monoclonal antibodies. Antimicrob Agents Chemother 1993; 37: 2490-2
191. Hopt UT, Pfeffer F. Schareck W, et al. Ganciclovir for prophylaxis of CMV disease after pancreas/kidney transplantation. Transplant Proc 1994; 26: 434-5
192. Hibberd PL, Tolkoff-Rubin NE, Conti D, et al. Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients. A randomized controlled trial. Ann Intern Med 1995; 123: 18-26
193. MetselaarHJ, RothbarthPH, BrouwerRM, elal. Prevention of cytomegalovirus-related death by passive immunization. A double-blind placebo-controlled study in kidney transplant recipients treated for rejection. Transplantation 1989; 48: 264-6
194. Steinmuller DR, Novick AC, Slreen SB, et al. Intravenous immunoglobulin infusions for the prophylaxis of secondary cytomegalovirus infection. Transplantation 1990; 49: 68-70